Stock NKGN NKGEN BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News NKGen Biotech, Inc.

Equities

NKGN

US65488A1016

End-of-day quote Nasdaq
Other stock markets
 23:00:00 04/06/2024 BST 		5-day change 1st Jan Change
1.45 USD +0.69% Intraday chart for NKGen Biotech, Inc. -13.17% -47.27%
06-03 NKGen Biotech, Inc. To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 CI
05-23 NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology Annual Meeting CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
AQ
NKGen Biotech, Inc. To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
CI
Spotlighting Unexplored Stocks in Focus: NKGN, INBS, BTBT, PRSO, MGOL
AQ
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology Annual Meeting
CI
NKGen Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Sector Update: Health Care Stocks Softer Late Afternoon
MT
Top Midday Gainers
MT
Sector Update: Health Care Stocks Ease Monday Afternoon
MT
NKGen Biotech Cell Therapy Gets Clearance to Start Phase 2 Clinical Trial in Alzheimer's Disease; Shares Rise
MT
NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease
AQ
NKGen Biotech, Inc.?s SNK01 NK Cell Therapy Cleares to Start Phase 2 Clinical Trial in Alzheimer?s Disease
CI
NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition
AQ
NKGen Biotech, Inc. announced that it has received $0.2 million in funding from Meteora Capital, LLC, Glazer Capital, LLC
CI
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease
AQ
Nkgen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy in Parkinson's Disease
CI
NKGen Biotech, Inc. announced that it has received $0.55 million in funding from FirstFire Capital Management LLC, Meteora Capital, LLC, Glazer Capital, LLC, Meteora Strategic Capital, LLC, Sandia Investment Managment LP
CI
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
AQ
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology Annual Meeting
AQ
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NKGN Stock
  4. News NKGen Biotech, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW